How many clinical trials are studying Tepotinib?

4 recruiting trials in our tracked data involve Tepotinib.

What conditions is Tepotinib being studied for?

In our tracked recruiting trials, Tepotinib is being studied in trials for Lung cancer, Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation.

Tepotinib: clinical trials recruiting now

Q: Is Tepotinib FDA-approved?

Yes. According to the FDA drug label available through openFDA, Tepotinib is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Tepotinib appears in the FDA drug-label database. Marketed as TEPMETKO.

FDA-approved use

TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. ( 1 )

FDA label via openFDA

Phase breakdown

Phase 1 1 Phase 2 2 Phase 3 1

Conditions being studied

Condition	Trials
Lung cancer · Tepotinib for Lung cancer	4
Advanced Non Small Cell Lung Cancer	1
MET Exon 14 Mutation	1
Non-Small Cell Lung Cancer	1
Non-Small Cell Lung Cancer Metastatic	1
Recurrent Lung Non-Small Cell Carcinoma	1
Stage IV Lung Cancer AJCC v8	1

Recruiting trials involving Tepotinib

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
NCT07619339 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
NCT06106802 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688 · Phase: Phase 2 · Ages: 18 Minutes and older · Sex: All (male and female) · 266 locations
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations

Common questions

Is Tepotinib FDA-approved?

Yes, marketed as TEPMETKO.

How many recruiting trials involve Tepotinib?

4 recruiting trials across 7 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.